PROSPER Trial

	Low Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Physiology
Pathophysiology
Causes Low LDL High LDL
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Prognosis and Complications
Diagnosis
Laboratory Findings
Treatment
Medical Therapy
Landmark Trials
Future or Investigational Therapies
Case Studies
Case #1
PROSPER Trial On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of PROSPER Trial All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on PROSPER Trial
CDC on PROSPER Trial
PROSPER Trial in the news
Blogs on PROSPER Trial
Directions to Hospitals Treating Low density lipoprotein
Risk calculators and risk factors for PROSPER Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Click here to download slides for PROSPER.

Overview

Pravastatin 40 mg daily reduced the incidence of non-fatal MI and CHD death during a follow-up of 3.2 years, in this trial involving the 2804 elderly men and 3000 women with a history of, or risk factors for vascular disease. This trial extended the treatment strategies to elderly population^[1].

References

↑ Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM; et al. (2002). "Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial". Lancet. 360 (9346): 1623–30. PMID 12457784. Review in: ACP J Club. 2003 Jul-Aug;139(1):9

[pmid12457784-1] Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM; et al. (2002). "Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial". Lancet. 360 (9346): 1623–30. PMID 12457784. Review in: ACP J Club. 2003 Jul-Aug;139(1):9

[1]

v t e Lipopedia
Basic Science	Cholesterol • Triglyceride Lipoprotein metabolism and transport Lipoprotein: Chylomicron • Chylomicron remnant • HDL • IDL • LDL • Lipoprotein(a) • VLDL • Lipoprotein-X Apolipoprotein: APOA (1, 2, 4, 5) • APOB ( Apolipoprotein B-48, Apolipoprotein B-100) • APOC (1, 2, 3, 4) • APOD • APOE • APOH • APOJ • APOL • APOM • Apo(a) Lipoprotein receptor: LDL receptor • Soluble low density lipoprotein receptor-related protein (sLRP) • Apolipoprotein E Receptor 2 • Scavenger receptor • Scavenger receptor A • Scavenger receptor B • VLDL receptor Lipoprotein enzymes: Lipoprotein lipase • Lipoprotein-associated phospholipase A2 (Lp-PLA2) • Cholesterylester transfer protein ( Acetyl-CoA C-acyltransferase, Lecithin-cholesterol acyltransferase) • Microsomal triglyceride transfer protein • ABCA1 Genes: Low density lipoprotein receptor gene family • Microsomal triglyceride transfer protein • ABCA1
Lipoprotein Disorders	Lipoprotein disorders Primary lipoprotein disorders: Familial hyperchylomicronemia (Type I) • Familial hypercholesterolemia (Type IIA) • Familial combined hyperlipidemia (Type IIB) • Dysbetalipoproteinemia (Type III) • Primary hypertriglyceridemia (Type IV) • Mixed hyperlipoproteinemia (Type V) Secondary lipoprotein disorders
Abnormal Laboratory Lipid Profile	Low chylomicron • Low chylomicron remnant • Low HDL • Low IDL • Low LDL • Low lipoprotein(a) • Low VLDL High chylomicron • High chylomicron remnant • High HDL • High IDL • High LDL • High Lipoprotein(a) • High VLDL

PROSPER Trial

Overview

References

Navigation menu